Si-bone ( SIBN ) Q2 Revenue Jumps 22%
Si-bone ( NASDAQ:SIBN ) , a medical device innovator focused on minimally invasive surgery for joint dysfunction and pelvic conditions, released its second quarter 2025 results on August 4, 2025. The company reported GAAP revenue of $48.6 million and a GAAP net loss per share of $ ( 0.14 ) for Q2 ...
Si-Bone ( SIBN ) Reports Q2 Loss, Beats Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of +26.32% and +0.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance
Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow ...
Glaukos ( GKOS ) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of +7.69% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025
SANTA CLARA, Calif., July 29, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( Nasdaq: SIBN ) , a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. ...
SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 - SI-BONE ( NASDAQ:SIBN )
SANTA CLARA, Calif., July 29, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. SIBN, a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will ...
SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025
SANTA CLARA, Calif., July 14, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( Nasdaq: SIBN ) , a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the second quarter of 2025 after market close on Monday, August 4, 2025.
All You Need to Know About Si-Bone ( SIBN ) Rating Upgrade to Buy
Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SI-BONE to Truist Securities MedTech Conference on June 17, 2025
SANTA CLARA, Calif., June 04, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( Nasdaq: SIBN ) , a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. ...
SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025
SANTA CLARA, Calif., May 28, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( Nasdaq: SIBN ) , a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Goldman Sachs 46th Global Healthcare Conference in Miami ...
Wall Street Analysts See a 34.22% Upside in Si-Bone ( SIBN ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Si-Bone ( SIBN ) a Strong Momentum Stock: Buy Now?
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Si-Bone ( SIBN ) Could Surge 41.21%: Read This Before Placing a Bet
The consensus price target hints at a 41.2% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Si-Bone ( SIBN ) Reports Q1 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of 37.50% and 5.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025
SANTA CLARA, Calif., April 14, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( Nasdaq: SIBN ) , a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first quarter of 2025 after market close on Monday, May 5, 2025.
SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025 - SI-BONE ( NASDAQ:SIBN )
SANTA CLARA, Calif., April 14, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. SIBN, a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first quarter of 2025 after market close on Monday, May 5, 2025.
IQVIA ( IQV ) Moves 8.7% Higher: Will This Strength Last?
IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - EyePoint Pharmaceuticals ( NASDAQ:EYPT ) , Cormedix ( NASDAQ:CRMD )
U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Friday. Shares of Li Auto Inc. LI fell sharply in today's pre-market trading after the company reported fourth-quarter results. Li Auto posted quarterly adjusted EPADS of 52 cents, up from 30 cents in ...
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Applied Optoelectronics ( NASDAQ:AAOI ) , Bit Origin ( NASDAQ:BTOG )
Shares of Rubrik, Inc. RBRK rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates. Rubrik reported quarterly losses of 61 cents per share, which beat the analyst consensus ...
Si-Bone ( SIBN ) Reports Q4 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of 31.25% and 0.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance
Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter ...
Si-Bone ( SIBN ) Expected to Beat Earnings Estimates: Should You Buy?
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVRx ( CVRX ) Reports Q4 Loss, Tops Revenue Estimates
CVRx (CVRX) delivered earnings and revenue surprises of -16.22% and 0.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025
SANTA CLARA, Calif., Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( Nasdaq: SIBN ) , a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on ...
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025 - SI-BONE ( NASDAQ:SIBN )
SANTA CLARA, Calif., Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. SIBN, a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February ...
Osteotec announces exclusive partnership with Highridge Medical to distribute spine surgery solutions in the UK
NEWBURY, England, Jan. 21, 2025 /PRNewswire/ -- Osteotec, the market leading manufacturer and distributor of specialised medical devices, is pleased to announce an exclusive distribution agreement with Highridge Medical.
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - C&F Financial ( NASDAQ:CFFI ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Southwest Airlines Co. LUV fell sharply in today's pre-market trading. The U.S.
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - ANI Pharmaceuticals ( NASDAQ:ANIP ) , AEON Biopharma ( AMEX:AEON )
Shares of Taiwan Semiconductor Manufacturing Company Limited TSM rose sharply in today's pre-market trading after the company announced fourth-quarter results. Taiwan Semiconductor Mfg. said net profit climbed 57% year-over-year to a record T$374.68 billion ( $11.38 billion ) .
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday - Agilon Health ( NYSE:AGL ) , Biogen ( NASDAQ:BIIB )
U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Monday. Shares of Intra-Cellular Therapies, Inc. ITCI rose sharply during Monday's session after Johnson & Johnson agreed to acquire the company for $132.00 per share in cash for a total equity value of approximately ...
Wall Street Analysts Believe Si-Bone ( SIBN ) Could Rally 64.71%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Osteotec appointed as exclusive distributor for Cerapedics in the UK and Ireland
NEWBURY, England, Dec. 11, 2024 /PRNewswire/ -- Osteotec, the market leading manufacturer and distributor of specialised medical devices, is pleased to announce an exclusive agreement to distribute Cerapedics' clinically proven i-FACTOR bone graft portfolio in the UK and Ireland.
Wall Street Analysts See an 83.56% Upside in Si-Bone ( SIBN ) : Can the Stock Really Move This High?
The consensus price target hints at an 83.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
SANTA CLARA, Calif., Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( Nasdaq: SIBN ) , a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York.
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 - SI-BONE ( NASDAQ:SIBN )
SANTA CLARA, Calif., Nov. 20, 2024 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. SIBN, a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York.
Si-Bone ( SIBN ) Reports Q3 Loss, Lags Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of 27.27% and 0.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Nuwellis, Inc. ( NUWE ) Q3 Earnings Surpass Estimates
Nuwellis (NUWE) delivered earnings and revenue surprises of 297.73% and 1.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Artivion ( AORT ) Tops Q3 Earnings and Revenue Estimates
Artivion (AORT) delivered earnings and revenue surprises of 300% and 0.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Steris ( STE ) Surpasses Q2 Earnings Estimates
Steris (STE) delivered earnings and revenue surprises of 1.42% and 0.58%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™ - SI-BONE ( NASDAQ:SIBN )
SANTA CLARA, Calif., Nov. 05, 2024 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc., SIBN, a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare & Medicaid Services ( CMS ) has granted Transitional ...
Strength Seen in Si-Bone ( SIBN ) : Can Its 6.9% Jump Turn into More Strength?
Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024
SANTA CLARA, Calif., Oct. 22, 2024 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( Nasdaq: SIBN ) , a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024.
SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024 - SI-BONE ( NASDAQ:SIBN )
SANTA CLARA, Calif., Oct. 22, 2024 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. SIBN, a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024.
SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device
SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.
SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation
SANTA CLARA, Calif., Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. ( Nasdaq: SIBN ) , a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, ...
SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation - SI-BONE ( NASDAQ:SIBN )
SANTA CLARA, Calif., Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. SIBN, a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ ...
SI-BONE Receives FDA Nod for Its TNT Implant System - Quest Diagnostics ( NYSE:DGX ) , Intuitive Surgical ( NASDAQ:ISRG )
SI-BONE, Inc. SIBN has recently received FDA 510 ( k ) clearance for its iFuse TORQ TNT implant system ( "TNT" ) . The TNT implant system is the first anatomy-specific system designed to meet the biomechanical challenges presented by pelvic fragility fractures.
Wall Street Analysts Think Si-Bone ( SIBN ) Could Surge 40.3%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 40.3% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SI-BONE ( SIBN ) Receives FDA Nod for Its TNT Implant System
SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.
SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024 - SI-BONE ( NASDAQ:SIBN )
SANTA CLARA, Calif., Aug. 22, 2024 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc. SIBN, a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York.
SI-BONE, Inc. Receives 510 ( k ) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System
SANTA CLARA, Calif., Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- SI-BONE, Inc., ( Nasdaq: SIBN ) , a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510 ( k ) clearance of the iFuse TORQ TNT™ Implant System ( TNT ) .
